Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022.
October 24, 2023 at 04:03 pm EDT
Share
From July 1, 2023 to September 30, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,009,315 shares, representing 3.26% for $191.17 million under the buyback announced on October 24, 2022.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
MEDPACE HOLDINGS, INC. 
